(CercleFinance.com) – Johnson & Johnson announced that it has successfully completed the acquisition of Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop antibody-drug conjugates (ADCs). ) new generation.
This acquisition strengthens Johnson & Johnson’s commitment to innovation in prostate cancer and deepens the portfolio of next-generation antibody drugs and targeted oncology treatments.
This all-cash transaction has a total value of approximately $2.0 billion.
This acquisition represents a unique opportunity for Johnson & Johnson to design, develop and commercialize targeted therapeutic products in oncology.
‘ Ambrx’s proprietary ADC technology integrates the benefits of highly specific targeting of monoclonal antibodies securely linked to a powerful chemotherapeutic payload to achieve targeted and effective killing of cancer cells without the common side effects typically associated with chemotherapy’.
“We look forward to further development of ARX517, which represents the first and best potential PSMA-targeting ADC for the treatment of metastatic castration-resistant prostate cancer,” said Yusri Elsayed, MD, MHSc, PhD , Global Therapeutic Sector Leader, Oncology, Johnson & Johnson Innovative Medicine.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on JOHNSON & JOHNSON in real time: